RICHARD GAYNOR

CIK 1741284 · President of R&D · last filed 2026-05-22

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.62M

Companies

4

Total Filings

33

Lifetime Open-Market Net

-$189.1K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ALKS Director 37,226 $44.28 $1.65M $0 16 2026-05-22
ZLAB Director 56,630 $17.07 $966.7K -$103.7K 7 2026-03-19
INFINITY PHARMACEUTICALS, INC. (INFI) Delisted Director $0.04 $0 3 2022-06-16
Neon Therapeutics, Inc. (NTGN) Delisted President of R&D 0 -$85.4K 7 2020-05-06

Recent Filings · Page 2 of 4

33 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2024-06-04 ALKS Mixed $0 EDGAR
2023-07-10 ALKS Mixed +4,527 -$42.7K EDGAR
2023-06-30 ALKS Grant (A) $0 EDGAR
2023-06-30 ZLAB Grant (A) +18,903 $500.0K EDGAR
2022-07-08 ALKS Grant (A) $0 EDGAR
2022-06-16 INFINITY PHARMACEUTICALS, INC. (INFI) Delisted Grant (A) $0 EDGAR
2022-06-16 ALKS Mixed +6,890 -$18.9K EDGAR
2021-12-03 ALKS Mixed +4,239 -$29.6K EDGAR
2021-11-22 ZLAB Grant (A) +8,912 $0 EDGAR
2021-06-16 ALKS Grant (A) $0 EDGAR
Showing 1120 of 33
Page 2 of 4
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.